

Effective from 1<sup>st</sup> Aug 2017, Valid up to 30<sup>th</sup> July 2019

### Title: Continuing Review of Study Protocols

SOP Code: SOP 07/V5 dated 26<sup>th</sup> July 2017

Authors:

Dr. Sharmila Jalgaonkar (Member Secretary, IEC - I) Yo Jalyaanka 4 Such Dr. Snehalata Gajbhiye (Member Secretary, IEC-II)

#### Reviewed by:

Dr. Urmila Thatte (Member, IEC - I)	Umnhalt
Dr. Padmaja Marathe (Member, IEC-II)	Padmaja Marathe

### Approved by:

10M Dr. Padmavathy Menon,

Chairperson, IEC - I (Signature with Date)

nert

Dr. Alan Almeida, Chairperson, IEC - II (Signature with Date)

### Table of Contents:

No.	Contents	Page No.
1	Purpose	2
2	Scope	2
3	Responsibility	2
4	Flow Chart	2
5	Detailed Instructions	2
6	References	4
7	Annexure	4



## 1. Purpose

The purpose of this Standard Operating Procedure is to describe how continuing reviews of previously approved protocols are managed by the Institutional Ethics Committee (IEC). The purpose of the continuing review is to monitor the progress of the entire study, not just the changes in it, to ensure continuous protection of the rights and welfare of research participants.

### 2. Scope

This SOP applies to conducting any continuing review of study protocols involving research participants at intervals appropriate to the degree of risk. All the projects approved by the Institutional Ethics Committee will be reviewed at least once a year. Depending upon the degree of risk to the participants, the nature of the studies, the vulnerability of the study participants and duration of the study, the IEC may choose to review or monitor the protocols more frequently.

### 3. Responsibility

It is the responsibility of the IEC Secretariat to remind the IEC and the principal investigators regarding study protocols that should be continuously reviewed. All the approved protocols will be reviewed annually (at least once a year). The Chairperson is responsible for determining the date of continuing review if the project will be reviewed more frequently in the year. This decision is taken during the IEC meeting wherein the project is finally approved or can be taken subsequently based on the SAE reports, monitoring reports, adequacy documentation procedures followed by the investigators or new safety data received.

The IEC is responsible for reviewing the progress made in the protocol, the occurrence of unexpected events or problems, and the rate of accrual of participants.

### 4. Flow chart

No.	Activity	Responsibility
1	Determine the date of continuing review and	IEC Secretariat
	Notify the Principal Investigator or study team	
2.	Manage continuing review package upon receipt	IEC Secretariat
	and distribute to member secretary/chairperson	
3.	Assign reviewers and review the annexure/	Chairperson / Member Secretary / IEC
	related documents of continuing review	Members
4.	Written communication of the IEC decision to investigator	IEC Secretariat

### 5. Detailed Instructions

### 5.1. Determine the date of continuing review and Notify the Principal Investigator or study team

### a. Determining the date of continuing review

• The Administrative Officer will look through the document archives/master chart of projects approved by the IEC for the due date of continuing reviews.



**Continuing Review of Study Protocols** 

The Secretariat will plan for continuing review of annual progress reports to be reviewed as close as possible to the due date or the anniversary of the effective date (date of original approval) of the protocol.

# b. Notifying the Principal Investigator or the study team

- If the Principal Investigator fails to submit the Continuing review report within one month of the due date (i.e. 11<sup>th</sup> months from the date of approval, unless specified otherwise), the IEC secretariat will send a reminder as per the format mentioned in AX 01/SOP 07/V5 within 7 working days of this due date. If there is no response within 15 days after the date of reminder, the IEC secretariat will put up the matter for discussion at the forthcoming full board meeting for appropriate action which may consist of but not limited to
  - a) A letter of reprimanding the Investigator.

Not reviewing future projects from the PI for a specified period of time / till the submission of status report of the previous study.

b) A letter asking the Investigator to put recruitment of new participants on hold.

# 5.2 Managing the continuing review package upon receipt.

- The Secretariat will receive a package (soft and hard copy) submitted by the Study Team of continuing review for each approved protocol. The Secretariat will make sure that the contents of the package include the following documents:
  - Continuing Review Application Form (AX 02/SOP 7/V5) duly filled with an explanation for any "yes" (ticked on the Continuing Review Application Form (AX 02/SOP 07/V5) answers on the application form and a discussion of scientific development, either through the conduct of this study or similar research that may alter risks to research participants. The changes in the selection criteria of participants, protocol/Informed consent Document amendments, changes in the study team, any unexpected complications etc. have to be discussed in the attached narrative.
  - $\triangleright$ The Secretariat will check for complete information and for the presence of the required signatures of the Principal Investigator in the Continuing Review Application Form. The secretariat will ensure the payment of Rs 10,000 for Pharma sponsored studies and Rs 1000/- for Government sponsored studies. The Secretariat will forward the continuing review report to the Member Secretary/ Chairperson.

## 5.3 Assign reviewers and review the annexure/ related documents of continuing review

The Chairperson /Member Secretary will review the Continuing Review Application Form (AX 02/SOP 07/V5). The Chairperson / member secretary can designate one/two IEC members to review the Study report and related documents and inform the decision to the other IEC members at the next full board meeting.

## **Review of Continuing Review Application**

The Continuing review submission may undergo expedited review (as per the procedure described in SOP 05-B/V5) or full board review (as per the procedure described in SOP 05-A/V5) as deemed appropriate by the IEC Chairperson/ Member Secretary



- The IEC Chairperson/ Member Secretary/ Member/s could reach one of the following decisions after review:
  - 1. Noted : The IEC approves the continuation of the above mentioned project without any modifications (as per the format *AX 03/SOP 07/V5* )
  - 2. Modifications recommended: Protocols that have been suggested modifications by the IEC may not proceed until the conditions set by the IEC in the decision have been met. Protocols should be amended and submitted to the IEC within one month for re-review.
  - 3. The project cannot be continued: The reasons for discontinuation of the project will be mentioned in the letter notifying the decision to the Principal Investigator.
  - 4. The decision will also include any significant findings that have arisen during review process and this will be communicated to Principal Investigator. It is the responsibility of Principal Investigator to provide this information to the participants and once done submit the report to IEC.

### 5.4 Written communication of the IEC decision to investigator

- ✓ The decision will be communicated to the PI within 14 days and for the continuing review reports which will be discussed in the full board meeting the decision will be communicated within 14 days of the meeting.
- ✓ The Secretariat will record the decision reached on the proposed continuing review report in the minutes of the meeting.

### 6. References

- World Health Organization, Operational Guidelines for Ethics Committees that Review Biomedical Research, (Geneva 2000) - <u>www.who.int/tdr/publications/publications/</u> (last accessed 31<sup>st</sup> July 2017)
- International Conference on Harmonization, Guidance on Good Clinical Practice (ICH GCP) 1996- <u>http://www.ich.org/LOB/media/MEDIA482.pdf</u> (last accessed 31<sup>st</sup> July 2017)

### 7. Annexure

- Annexure 1 AX 01/SOP 07/V5 Reminder letter by the IEC to investigator
- Annexure 2 AX 02/SOP 07/V5 Continuing Review Application Form
- Annexure 3 AX 03/SOP 07/V5 Continuing Review report Approval Letter

### Annexure 1

#### AX 01/SOP 07/V5

### Reminder letter by the IEC to Investigator

Date:-

Name of Principal Investigator:-

Department:-



Effective from 1<sup>st</sup> Aug 2017, Valid up to 30<sup>th</sup> July 2019

### Ref: - Project Title: XXXXXX

The above referenced project was approved by the IEC-I on **xxxx** and will due for the continuing Annual Review by the IEC-I. You are requested to submit an Annual Status Report in one of the prescribed format as given below at the earliest on or before **xxx** 

a) If ongoing, status report in the format as per form no. (AX 02/SOP 07/V5)

b) If completed – status report in the format as per form no. (AX 01/SOP 08/V5)

c) If terminated / not initiated - status report in the format as per form no. (AX 01/SOP 09/V5)

Signature with date \_\_\_\_\_

Member Secretary \_\_\_\_\_

### Annexure 2

AX 02/SOP 07/V5

### **Continuing Review Application Form**

Date: \_\_\_\_\_

Protocol No.:	Date of IEC approval:
Protocol Title:	
Principal Investigator :	
Department :	
Summary of protocol participants:	Has any information appeared in the literature, or
No. of participants approved by IEC	evolved from this or similar research that might affect the IEC/IEC's evaluation of the risk/benefit
No. of recruited participants	analysis of participants involved in this protocol?
No. of ongoing participants	□ No
No. of Completed participants	Yes (attach separate sheet if needed)
No. of participants who refused to consent	
Have any participants been withdrawn from this	Have any unexpected complications or SAEs been
study?	noted since last review at our site?
□ No	<ul> <li>No</li> <li>Yes (attach separate sheet if needed)</li> </ul>
Yes (state the number and reasons for drop-outs	<ul> <li>No. of patients who had SAEs</li> </ul>
of each participant, attach separate sheet if	□ Whether reports of SAEs at have been

SEME TEMH	Institutional Ethics Committee ( Seth G.S. Medical College and K.E.M. Parel, Mumbai – 400 012. Web: www.kem.edu Continuing Review of Study Pro	Hosp		SOP 07/V5 Effective from 1 <sup>st</sup> Aug 2017, Valid up to 30 <sup>th</sup> July 2019	
needed)         Impaired participants         None         Physically         Cognitively         Both         Have there been any amendments in protocol/ Informed Consent Document since the last review?         NO         YES         Were these protocol/ Informed Consent Document (ICD) amendments approved by IEC?         No         Yes         If no, mention the amendments not approved		or L	Whet been Types partic Numb Numb Ve any withdr No Yes (Io narrat	itted to the IEC	os. of
Which protocol amendment is the site following at this date Which ICD amendment is the site following at this date		av av Ha co thi	<ul> <li>Yes (submit as an attachment)</li> <li>Have any investigators developed equity or consultative relationship with a source related to this protocol which might be considered a conflict of interest?</li> <li>No</li> </ul>		ted to

Signature of the Principal Investigator with Date:

### Annexure 3

# AX 03/SOP 07/V5

Continuing Review report Approval Letter

Name of the Principal Investigator:-



### Department :-

Ref: - Project Title: \_\_\_\_\_\_ Sub: - Letter dated: \_\_\_\_\_\_

This is with reference to the above stated letter regarding the continuing review report of the above mentioned project. The Continuing Review Report was reviewed in the IEC meeting held on XXXXXXXX and was noted.

The IEC allows continuation of the above mentioned project without any modifications.

You are requested to submit the next continuing review report within 1 month of the due date i.e. on or before XXXXX.

Signature with date Member Secretary

Date of approval: